Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2018

Feb 14, 2019

SELL
$30.43 - $56.65 $422,977 - $787,435
-13,900 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$46.46 - $68.49 $645,794 - $952,010
13,900 New
13,900 $847,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $201M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Paloma Partners Management CO Portfolio

Follow Paloma Partners Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Paloma Partners Management CO with notifications on news.